Skip to main content
S&P 5007,562.96-0.30%DOW51,663.08-0.83%NASDAQ26,015.57+0.13%BTC$75,791.00+0.23%ETH$2,402.19+0.32%GOLD$4,342.30+0.22%OIL$102.35-3.29%
Smart Investors Daily
RA

NASDAQ · RAPP

Rapport Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$42.68

Down-$1.00 (-2.34%)

Updated Sep 16, 2026, 6:56 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.05B
P/E ratio
-111.89
Dividend yield
0.00%
52-week range
$26.01 – $52.93
Volume
189.31K
Avg. volume
522.83K

Price performance

RAPP price history

1M range · 20 trading sessions · Daily adjusted prices

RAPP closed at $42.68 after 20 trading sessions, down 12.92% for the selected period.

Last close
$42.68
Period change
-12.92%
Period low
$42.68
Period high
$52.50
Daily close
View OHLC price history
RAPP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$43.87$43.98$41.76$42.68189.31K
Sep 14, 2026$44.30$44.90$43.36$44.00196.93K
Sep 11, 2026$44.21$44.30$43.01$43.62251.79K
Sep 10, 2026$43.35$43.995$42.65$43.46319.26K
Sep 9, 2026$45.17$45.42$43.13$43.885437.74K
Sep 8, 2026$45.01$47.00$44.67$46.09489.39K
Sep 4, 2026$47.63$48.00$45.52$45.77279.88K
Sep 3, 2026$48.85$49.135$47.08$47.65276.96K
Sep 2, 2026$48.50$50.34$47.73$48.69294.75K
Sep 1, 2026$48.17$49.375$47.90$48.56148.6K
Aug 31, 2026$48.72$49.325$47.51$48.67221.02K
Aug 28, 2026$50.15$50.6751$48.37$48.77332.73K
Aug 27, 2026$51.88$52.93$50.60$50.83382.83K
Aug 26, 2026$50.95$52.83$50.01$52.50275.27K
Aug 25, 2026$49.88$51.38$49.0001$51.17324.5K
Aug 24, 2026$48.16$50.34$47.4369$49.33365.42K
Aug 21, 2026$48.36$48.50$47.48$48.24140.87K
Aug 20, 2026$48.58$48.775$47.00$47.85323.72K
Aug 19, 2026$49.58$49.90$48.62$49.07232.32K
Aug 18, 2026$47.81$49.37$47.73$49.01214.73K

Latest RAPP news

The latest Smart Investors Daily articles mentioning RAPP.

Stock researchCompany · Overview

RAPP research

Overview

Company profile and research snapshot.

Company profile

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.00
Implied upside
—
Analysts
—
RAPP recent ratings
DateFirmRatingTarget
Sep 16, 2026BTIGBuy—
Aug 19, 2026BTIGBuy—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 5, 2026BTIGBuy—
Jul 16, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 202

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By